손주혁 교수 연구실
article|
인용수 315
·2024
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Aditya Bardia, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H. Barrios, Joyce O’Shaughnessy, Hans Wildiers, Jean‐Yves Pierga, Qingyuan Zhang, Cristina Saura, Laura Biganzoli, Joohyuk Sohn, Seock‐Ah Im, Christelle Lévy, William Jacot, Natasha Begbie, Jun Ke, Gargi Patel, Giuseppe Curigliano
IF 78.5New England Journal of Medicine
초록
Among patients with hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer who had received one or more lines of endocrine-based therapy, treatment with trastuzumab deruxtecan resulted in longer progression-free survival than chemotherapy. No new safety signals were identified. (Funded by AstraZeneca and Daiichi Sankyo; DESTINY-Breast06 ClinicalTrials.gov number, NCT04494425.).
키워드
TrastuzumabMedicineMetastatic breast cancerOncologyBreast cancerEndocrine systemInternal medicineCancerHormone